{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:57:40Z","timestamp":1778558260294,"version":"3.51.4"},"reference-count":124,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.09.013","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T13:41:30Z","timestamp":1539006090000},"page":"7072-7082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Herpes zoster in the context of varicella vaccination \u2013 An equation with several variables"],"prefix":"10.1016","volume":"36","author":[{"given":"Peter","family":"Wutzler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Casabona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Cnops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esse Ifebi Herve","family":"Akpo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aurelio P.","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.013_b0005","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper, June 2014","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.09.013_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10198-003-0200-7","article-title":"The burden of varicella in Germany. Potential risks and economic impact","volume":"5","author":"Banz","year":"2004","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2018.09.013_b0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12889-015-1514-y","article-title":"The humanistic, economic and societal burden of herpes zoster in Europe: a critical review","volume":"15","author":"Gater","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2018.09.013_b0020","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.013_b0025","first-page":"1766","article-title":"Current and future effects of varicella and herpes zoster vaccination in Germany \u2013 insights from a mathematical model in a country with universal varicella vaccination","volume":"12","author":"Horn","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.013_b0030","doi-asserted-by":"crossref","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","article-title":"Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries","volume":"8","author":"Poletti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.09.013_b0035","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bulm.1999.0126","article-title":"Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles","volume":"61","author":"Schuette","year":"1999","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0040","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"van Hoek","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.013_b0045","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.03.052","article-title":"Varicella zoster virus: a common cause of stroke in children and adults","volume":"25","author":"Amlie-Lefond","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0050","series-title":"The Pink Book: epidemiology and prevention of vaccine-preventable diseases","first-page":"353","article-title":"Varicella","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.vaccine.2018.09.013_b0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/INF.0b013e3181586665","article-title":"The burden of varicella complications before the introduction of routine varicella vaccination in Germany","volume":"27","author":"Liese","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0060","first-page":"16","article-title":"The clinical and epidemiological evolution of varicella in Romania during 2004 and 2013","volume":"8","author":"Rafila","year":"2015","journal-title":"J Med Life"},{"key":"10.1016\/j.vaccine.2018.09.013_b0065","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1111\/apa.12535","article-title":"Chickenpox and stroke in children: case studies and literature review","volume":"103","author":"Reis","year":"2014","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vaccine.2018.09.013_b0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cid\/cit659","article-title":"Chickenpox and risk of stroke: a self-controlled case series analysis","volume":"58","author":"Thomas","year":"2014","journal-title":"Clin Infect Diseases: Official Publ Infect Diseases Soc Am"},{"key":"10.1016\/j.vaccine.2018.09.013_b0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-7-26","article-title":"Varicella vaccination in Europe \u2013 taking the practical approach","volume":"7","author":"Bonanni","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0080","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00431-005-1637-8","article-title":"Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents","volume":"164","author":"Bonhoeffer","year":"2005","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2018.09.013_b0085","unstructured":"SAGE VZV Working Group. Varicella disease burden and varicella vaccines. Presented at WHO SAGE Meeting, April 2, 2014. [cited Available from http:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/april\/2_SAGE_April_VZV_Seward_Varicella.pdf?ua=1&ua=1 [Accessed 06 June 2017]."},{"key":"10.1016\/j.vaccine.2018.09.013_b0090","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jped.2015.10.003","article-title":"Varicella zoster virus related deaths and hospitalizations before the introduction of universal vaccination with the tetraviral vaccine","volume":"92","author":"de Martino","year":"2016","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vaccine.2018.09.013_b0095","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.09.013_b0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1753-6405.2007.00027.x","article-title":"An outbreak of chickenpox at a child care centre in Western Australia. Costs to the community and implications for vaccination policy","volume":"31","author":"Vally","year":"2007","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2018.09.013_b0105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1542\/peds.2013-0698","article-title":"Economic evaluation of the routine childhood immunization program in the United States, 2009","volume":"133","author":"Zhou","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.09.013_b0110","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/adc.2007.126243","article-title":"Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997\u20132005","volume":"93","author":"Quian","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2018.09.013_b0115","unstructured":"World Health Organization [Internet]. World Health Organization; c2016. WHO vaccine-preventable diseases: monitoring system. 2016 global summary, varicella [cited 14 December 2016]. Available from: http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules.html [cited Available]."},{"key":"10.1016\/j.vaccine.2018.09.013_b0120","unstructured":"Centers for Disease Control and Prevention. Varicella Active Surveillance Project. Available from: https:\/\/www.cdc.gov\/chickenpox\/surveillance\/vasp.html [Accessed 11 August 2017]. 2016."},{"key":"10.1016\/j.vaccine.2018.09.013_b0125","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.13.19530-en","article-title":"Impact of the routine varicella vaccination programme on varicella epidemiology in Germany","volume":"15","author":"Siedler","year":"2010","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.09.013_b0130","unstructured":"World Health Organization [Internet]. World Health Organization; c2017. Grading of scientific evidence \u2013 table II: Effectiveness of 2 doses against all varicella [cited 08 August 2017]. Available from: http:\/\/www.who.int\/entity\/immunization\/position_papers\/varicella_grad_effectiveness_2_doses.pdf [cited Available]."},{"key":"10.1016\/j.vaccine.2018.09.013_b0135","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","article-title":"Varicella vaccination \u2013 the global experience","volume":"16","author":"Wutzler","year":"2017","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13054-017-1731-0","article-title":"Severe varicella-zoster virus pneumonia: a multicenter cohort study","volume":"21","author":"Mirouse","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.vaccine.2018.09.013_b0145","series-title":"Vaccines","first-page":"836","article-title":"Varicella vaccine","author":"Gershon","year":"2013"},{"key":"10.1016\/j.vaccine.2018.09.013_b0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/INF.0000000000000476","article-title":"Incidence of pneumococcal and varicella disease in HIV-infected children and adolescents in the United Kingdom and Ireland, 1996\u20132011","volume":"34","author":"Payne","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/INF.0b013e3181fe0868","article-title":"The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children","volume":"30","author":"Taweesith","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0160","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/652798","article-title":"Effectiveness of varicella vaccine in children infected with HIV","volume":"201","author":"Son","year":"2010","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2018.09.013_b0165","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1093\/infdis\/174.Supplement_3.S320","article-title":"Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada","volume":"174","author":"LaRussa","year":"1996","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.09.013_b0170","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1086\/522155","article-title":"Varicella among adults: data from an active surveillance project, 1995\u20132005","volume":"197","author":"Marin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0175","doi-asserted-by":"crossref","first-page":"20552","DOI":"10.2807\/1560-7917.ES2013.18.32.20552","article-title":"Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012","volume":"18","author":"Garcia Cenoz","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.09.013_b0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2471\/BLT.13.132142","article-title":"Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study","volume":"92","author":"Heywood","year":"2014","journal-title":"Bull World Health Organ"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.09.013_b0185","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1086\/522156","article-title":"Changing varicella epidemiology in active surveillance sites\u2013United States, 1995\u20132005","volume":"197","author":"Guris","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0190","doi-asserted-by":"crossref","first-page":"e1134","DOI":"10.1542\/peds.2013-0863","article-title":"Impact of a routine two-dose varicella vaccination program on varicella epidemiology","volume":"132","author":"Bialek","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.09.013_b0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1469-0691.2004.00853.x","article-title":"Empirical data on the varicella situation in Germany for vaccination decisions","volume":"10","author":"Wagenpfeil","year":"2004","journal-title":"Clin Microbiol Infect: Official Publ Eur Soc Clin Microbiol nd Infect Diseases"},{"key":"10.1016\/j.vaccine.2018.09.013_b0200","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.09.013_b0205","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Aging, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"New England J Med"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.09.013_b0210","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol: Official Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0215","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0220","first-page":"109","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vacc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0225","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for herpes zoster: a systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0230","doi-asserted-by":"crossref","first-page":"ofw119","DOI":"10.1093\/ofid\/ofw119","article-title":"Risk factors for herpes zoster among adults","volume":"3","author":"Marin","year":"2016","journal-title":"Open Forum Infect Diseases"},{"key":"10.1016\/j.vaccine.2018.09.013_b0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/bmj.37991.511829.F7","article-title":"Case-control study of the effect of mechanical trauma on the risk of herpes zoster","volume":"328","author":"Thomas","year":"2004","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.vaccine.2018.09.013_b0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01570380","article-title":"Herpes zoster as a complication of a face lift","volume":"12","author":"Bailey","year":"1988","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.vaccine.2018.09.013_b0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1096-9071(200009)62:1<42::AID-JMV7>3.0.CO;2-C","article-title":"Reactivation of varicella-zoster virus in delayed facial palsy after dental treatment and oro-facial surgery","volume":"62","author":"Furuta","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0255","first-page":"323","article-title":"The natural history of shingles. Events associated with reactivation of varicella-zoster virus","volume":"20","author":"Juel-Jensen","year":"1970","journal-title":"J Roy College General Pract"},{"key":"10.1016\/j.vaccine.2018.09.013_b0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.30","article-title":"Herpes zoster and postherpetic neuralgia","volume":"9","author":"Johnson","year":"2010","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0265","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2018.09.013_b0270","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2018.09.013_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181565","article-title":"A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events","volume":"12","author":"Erskine","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.09.013_b0280","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12879-017-2278-z","article-title":"A meta-analysis of stroke risk following herpes zoster infection","volume":"17","author":"Marra","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0285","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.013","article-title":"Risk of stroke\/transient ischemic attack or myocardial infarction with herpes zoster: a systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jdv.13957","article-title":"European consensus-based (S2k) Guideline on the Management of Herpes Zoster \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment","volume":"31","author":"Werner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0295","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/749698","article-title":"The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany","volume":"2014","author":"Weinke","year":"2014","journal-title":"Sci World J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0300","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1532-5415.2007.01231.x","article-title":"Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster","volume":"55","author":"Dworkin","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","article-title":"The temporal impact of aging on the burden of herpes zoster","volume":"17","author":"Varghese","year":"2017","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.vaccine.2018.09.013_b0310","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults \u226550 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial","volume":"13","author":"Godeaux","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.013_b0315","unstructured":"Food and Drug Administration. Biologics License Application (BLA) Approval for Zoster Vaccine Recombinant, Adjuvanted. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581750.pdf [Accessed 14 June 2018] [cited Available]."},{"key":"10.1016\/j.vaccine.2018.09.013_b0320","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/infdis\/jit344","article-title":"Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults","volume":"208","author":"Mullane","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0325","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0330","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Diseases: Official Publ Infect Diseases Soc Am"},{"key":"10.1016\/j.vaccine.2018.09.013_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0340","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.09.013_b0345","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0350","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J Int Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0355","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.013_b0360","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0365","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0370","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1086\/378502","article-title":"Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0375","first-page":"2151","article-title":"Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus","volume":"31","author":"Park","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0380","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.vaccine.2018.09.013_b0385","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/vim.2010.0031","article-title":"Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents","volume":"24","author":"Ogunjimi","year":"2011","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0390","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(02)09837-9","article-title":"Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study","volume":"360","author":"Thomas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.09.013_b0395","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin Infect Diseases: Official Publ Infect Diseases Soc Am"},{"key":"10.1016\/j.vaccine.2018.09.013_b0400","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/jmv.21173","article-title":"Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts","volume":"80","author":"Cohrs","year":"2008","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0405","first-page":"39","article-title":"Successes and challenges in varicella vaccine","volume":"2","author":"Papaloukas","year":"2014","journal-title":"Ther Adv Vacc"},{"key":"10.1016\/j.vaccine.2018.09.013_b0410","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaad.2016.05.037","article-title":"Clinical and immunologic features of recurrent herpes zoster (HZ)","volume":"75","author":"Nakamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0415","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2011.02.030","article-title":"Subclinical reactivation of varicella zoster virus in all stages of HIV infection","volume":"304","author":"Birlea","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.09.013_b0420","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/infdis\/165.4.619","article-title":"Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA","volume":"165","author":"Devlin","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.epidem.2016.11.001","article-title":"Estimation of age-specific rates of reactivation and immune boosting of the varicella zoster virus","volume":"19","author":"Marinelli","year":"2017","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2018.09.013_b0430","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000024920","article-title":"Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals","volume":"41","author":"Schunemann","year":"1998","journal-title":"Intervirology"},{"key":"10.1016\/j.vaccine.2018.09.013_b0435","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/jmv.23605","article-title":"Varicella zoster virus quantitation in blood from symptomatic and asymptomatic individuals","volume":"85","author":"Toi","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0440","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/165.1.119","article-title":"Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation","volume":"165","author":"Wilson","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0445","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jmv.10555","article-title":"Stress-induced subclinical reactivation of varicella zoster virus in astronauts","volume":"72","author":"Mehta","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0450","doi-asserted-by":"crossref","first-page":"E245","DOI":"10.1111\/1469-0691.12131","article-title":"Subclinical VZV reactivation in immunocompetent children hospitalized in the ICU associated with prolonged fever duration","volume":"19","author":"Papaevangelou","year":"2013","journal-title":"Clin Microbiol Infect: Official Publ Eur Soc Clin Microbiol Infect Diseases"},{"key":"10.1016\/j.vaccine.2018.09.013_b0455","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.tripleo.2009.08.037","article-title":"Low prevalence of varicella zoster virus and herpes simplex virus type 2 in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy","volume":"109","author":"Wang","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.vaccine.2018.09.013_b0460","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07116","article-title":"Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster","volume":"4","author":"Ogunjimi","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.vaccine.2018.09.013_b0465","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","article-title":"The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination","volume":"28","author":"Civen","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0470","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1086\/430325","article-title":"Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992\u20132002","volume":"191","author":"Jumaan","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0475","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/INF.0000000000001249","article-title":"Update on incidence of herpes zoster among children and adolescents after implementation of varicella vaccination, antelope valley, CA, 2000 to 2010","volume":"35","author":"Civen","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0480","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/infdis\/jit405","article-title":"Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005\u20132009","volume":"208","author":"Weinmann","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.09.013_b0490","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","article-title":"Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster","volume":"28","author":"Brisson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.013_b0495","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.clinthera.2014.12.017","article-title":"The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix","volume":"37","author":"Ouwens","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2018.09.013_b0500","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.vaccine.2018.01.038","article-title":"Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway","volume":"36","author":"Marchetti","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.013_b0505","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1467-842X.2005.tb00248.x","article-title":"Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia","volume":"29","author":"Gidding","year":"2005","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2018.09.013_b0510","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41598-017-01024-8","article-title":"Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox","volume":"7","author":"Ogunjimi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.09.013_b0515","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.09.013_b0520","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/aje\/kwv240","article-title":"The epidemiology of herpes zoster after varicella immunization under different biological hypotheses: perspectives from mathematical modeling","volume":"183","author":"Guzzetta","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0525","doi-asserted-by":"crossref","first-page":"e0176845","DOI":"10.1371\/journal.pone.0176845","article-title":"The natural history of varicella zoster virus infection in Norway: further insights on exogenous boosting and progressive immunity to herpes zoster","volume":"12","author":"Marangi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.09.013_b0530","first-page":"20142509","article-title":"The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study","volume":"282","author":"Marziano","year":"2015","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.vaccine.2018.09.013_b0535","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/aje\/kws370","article-title":"Hope-Simpson's progressive immunity hypothesis as a possible explanation for herpes zoster incidence data","volume":"177","author":"Guzzetta","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0540","unstructured":"Talbird SELE, Mauskopf J, et al. Modeling the impact of exogenous boosting on herpes zoster: an updated methodological review of the varicella zoster virus literature. Presented at the International Society for Pharmacoeconomics and Outcomes Researc. Modeling the impact of exogenous boosting on herpes zoster: An updated methodological review of the varicella zoster virus literature. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 20-24, 2017, Boston, MA, USA Available from: https:\/\/www.ispor.org\/research_pdfs\/55\/pdffiles\/PRM80.pdf [Accessed 14 June 2018] [cited Available]."},{"key":"10.1016\/j.vaccine.2018.09.013_b0545","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2105\/AJPH.2009.160002","article-title":"Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination","volume":"100","author":"Donahue","year":"2010","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2018.09.013_b0550","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/infdis\/148.2.200","article-title":"Immunologic evidence of reinfection with varicella-zoster virus","volume":"148","author":"Arvin","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0555","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/421277","article-title":"Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus","volume":"190","author":"Vossen","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.013_b0560","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/cir436","article-title":"Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)?","volume":"53","author":"Gaillat","year":"2011","journal-title":"Clin Infect Diseases: Official Publ Infect Diseases Soc Am"},{"key":"10.1016\/j.vaccine.2018.09.013_b0565","unstructured":"Centers for Disease Control and Prevention. Shingles surveillance \u2013 Shingles Rates in People Older than 65 Years, United States, 1992\u20132010. Available from: https:\/\/www.cdc.gov\/shingles\/surveillance.html [Accessed 14 December 2016]. 2016."},{"key":"10.1016\/j.vaccine.2018.09.013_b0570","first-page":"1","article-title":"Trends in herpes zoster epidemiology in Germany based on primary care sentinel surveillance data, 2005\u20132016","author":"Zoch-Lesniak","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.013_b0575","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jinf.2015.01.015","article-title":"Temporal trends in herpes zoster-related hospitalizations in Madrid (Spain), 2003\u20132013","volume":"71","author":"Esteban-Vasallo","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.09.013_b0580","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40520-017-0782-z","article-title":"Temporal trends in herpes zoster-related hospitalizations in Italy, 2001\u20132013: differences between regions that have or have not implemented varicella vaccination","volume":"29","author":"Valente","year":"2017","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.vaccine.2018.09.013_b0585","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1017\/S0950268810001949","article-title":"Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization?","volume":"139","author":"Jardine","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.09.013_b0590","article-title":"Increasing trends of herpes zoster in Australia","volume":"10","author":"MacIntyre","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.09.013_b0595","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archderm.144.5.603","article-title":"Family history as a risk factor for herpes zoster: a case-control study","volume":"144","author":"Hicks","year":"2008","journal-title":"Arch Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.09.013_b0600","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1002\/jmv.10315","article-title":"Geographic and racial aspects of herpes zoster","volume":"70","author":"Nagasako","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.09.013_b0605","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4161\/hv.23334","article-title":"Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?","volume":"9","author":"Bilcke","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.013_b0610","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.013_b0615","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.09.013_b0620","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1067\/mpd.2001.116051","article-title":"Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy","volume":"139","author":"Vessey","year":"2001","journal-title":"J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18312623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:29:11Z","timestamp":1759400951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18312623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":124,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18312623"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster in the context of varicella vaccination \u2013 An equation with several variables","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}